Vyrix Pharmaceuticals plans to price initial public offering of stock

Aegis Capital and Fordham Financial Management to be joint bookrunners

By Devika Patel

Knoxville, Tenn., April 16 - Vyrix Pharmaceuticals, Inc. will conduct its initial public offering of common stock with a 45-day greenshoe, according to a Form S-1 filed Wednesday with the Securities and Exchange Commission.

Aegis Capital Corp. and Fordham Financial Management, Inc. are the joint bookrunning managers.

Proceeds will be used for clinical development, to repay a convertible promissory note the company issued to its parent company, for working capital, for capital expenditures and for other general corporate purposes.

The biopharmaceutical company is based in Greenwood Village, Colo. The company intends to list its common stock on the New York Stock Exchange under the symbol "VYRX."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.